HC Wainwright & Co. Reiterates Buy Rating on LB Pharmaceuticals Inc Common Stock (LBRX)

Market Context

LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector. The stock currently trades at $43.07 with a market capitalization of $508.8M.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for LB Pharmaceuticals Inc Common Stock.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for LB Pharmaceuticals Inc Common Stock

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 03, 2026	HC Wainwright & Co.	Buy	N/A
Jul 21, 2026	BMO Capital	Outperform	N/A
Jul 07, 2026	Wolfe Research	Outperform	N/A
Apr 27, 2026	HC Wainwright & Co.	Buy	N/A
Apr 10, 2026	Craig-Hallum	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View LBRX Stock Page